Pancreatic Cell News 10.09 March 12, 2019 | |
| |
TOP STORYPost-translational modification specifically compromised ribonucleotide reductase activity, leading to deficiency in dNTP pools, genomic DNA alterations with KRAS mutations, and cellular transformation. [Cell Metab] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISBeta Cell Secretion of miR-375 to HDL Is Inversely Associated with Insulin Secretion Scientists report that pancreatic islets and beta cells abundantly exported miR-375-3p to high-density lipoproteins (HDL) and this process was inhibited by cellular mechanisms that promoted insulin secretion. [Sci Rep] Full Article mRNA expression analysis of acinar-derived and duct-like cell fractions with concomitant immunocytochemical analysis of pancreatospheres revealed acquisition of an embryonic signature in the acinar-derived cells characterized by de novo expression of SOX9 and CD142, robust expression of PDX1 and surface expression of GP2. [Sci Rep] Full Article Researchers report on a novel technique to rescue implanted human pancreatic islets from the mouse kidney capsule. Using this model, they demonstrated that expression of the amino acid transporter SLC38A4 increased in α-cells following administration of a glucagon receptor blocking antibody. [Endocrinology] Abstract The authors demonstrated that treatment of mouse insulinoma MIN6 cells and human primary islets containing β-cells with palmitate increased asprosin expression and secretion. [Mol Cell Endocrinol] Abstract | Graphical Abstract PANCREATIC CANCERTGFBI, an ECM Interacting Protein, Enhances Glycolysis and Promotes Pancreatic Cancer Cell Migration Researchers demonstrated that, although usually secreted by stromal cells, pancreatic cancer cells synthesized and secreted TGFBI in quantities correlated with their migratory capacity. [Int J Cancer] Abstract Role of Nitric Oxide in Pancreatic Cancer Cells Exhibiting the Invasive Phenotype Investigators compared human pancreatic cancer cell line, PANC-1 and its invading phenotype (INV) collected from transwell inserts. INV exhibited higher resistance to carbon-ion radiation compared to whole cultured PANC-1, and had more efficient in vitro spheroid formation capability. [Redox Biol] Full Article Mechanical investigation revealed that WT1 associated protein could bind to and stabilize Fak mRNA, which in turn activated the Fak-PI3K-AKT and Fak-Src-GRB2-Erk1/2 signaling pathways. [Cancer Lett] Abstract Inhibition of laminin subunit beta-3 (LAMB3) abrogated the tumorigenic outcomes of PI3K/Akt signaling pathway activation, including those involving cell cycle arrest, cell apoptosis, proliferation, invasion and migration in vitro, and tumor growth and liver metastasis in vivo. [Cell Death Dis] Full Article Overexpression of DLEU2 significantly induced pancreatic cancer cell proliferation and invasion, whereas knockdown of DLEU2 impaired cell proliferation and invasion in vitro. [Cancer Sci] Abstract Investigators found that ribosomal protein S15A (RPS15A) expression was significantly up-regulated in pancreatic cancer cell lines. RPS15A knockdown resulted in a decrease of cell proliferation and colony formation, and induced cell cycle arrest in G0/G1 phases of pancreatic cancer cells in vitro. [Chem Biol Interact] Abstract | Graphical Abstract Subscribe to one of our other 19 science newsletters such as Hepatic Cell News & Intestinal Cell News. | |
| |
REVIEWSOrganoid Models for Translational Pancreatic Cancer Research Pancreatic ductal organoids are ex-vivo models of pancreatic ductal adenocarcinoma that can be established from very small biopsies, enabling the study of localized, advanced, and metastatic patients. Organoids models have been applied to pancreatic cancer research and offer a promising platform for precision medicine approaches. [Curr Opin Genet Dev] Full Article GAD65 Antibodies and Incident Type 2 Diabetes Mellitus The authors assess the association between glutamic acid decarboxylase (GAD65) antibody positivity and incident type 2 diabetes mellitus in a non-diabetic adult population. [Metabolism] Full Article Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSAzurRx BioPharma Announces Poster Presentation AzurRx BioPharma, Inc. announced a poster presentation. The poster will focus on data from its Phase II study of MS1819-SD in patients with chronic pancreatitis that was completed in 2018. [Press release from AzurRx BioPharma, Inc. discussing research to be presented at the 2019 Annual Meeting of the Americas Hepato-Pancreato-Biliary Association, Miami] Press Release | |
| |
INDUSTRY NEWSSTEMCELL Technologies Wins Deloitte Best Managed Companies Award STEMCELL Technologies announced that the company has been selected as a winner of Canada’s Best Managed Companies program for 2019. Canada’s Best Managed Companies is the country’s leading business awards program, recognizing excellence in the management abilities and practices of Canadian owned and managed companies with revenues over $15 million. [STEMCELL Technologies, Inc.] Press Release Zealand Pharma A/S announced the dosing of the first patient in the first Phase III trial to evaluate dasiglucagon as a potential treatment option for children with congenital hyperinsulinism. [Zealand Pharma A/S (GlobeNewswire, Inc.)] Press Release Implantable ‘Tea Bag’ in Development Releases Insulin for Children with Diabetes A $1.2 million grant from the JDRF will support University of Arizona researchers as they continue to perfect and test an implantable “tea bag” that senses glucose levels and automatically releases insulin when needed. [University of Arizona] Press Release | |
| |
POLICY NEWSVanderbilt Panel Weighs in Against Tenure for #MeToo Scientist A faculty grievance committee last month upheld a decision to deny tenure to BethAnn McLaughlin, a neuroscientist at the Vanderbilt University School of Medicine in Nashville who has become a prominent spokesperson for the #MeToo movement in science. [ScienceInsider] Editorial Ned Sharpless, Director of the National Cancer Institute, to Be Named Acting FDA Commissioner The Trump administration announced it would name Ned Sharpless, the director of the National Cancer Institute, the acting commissioner of the FDA next month. The announcement came just a week after the current commissioner, Scott Gottlieb, announced he plans to resign in early April. [STAT News] Editorial
| |
EVENTSNEW Advances in Metabolic Communication Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellowship – Pancreatic Islet Cells (Karolinska Institutet) NEW Postdoctoral Position – Diabetes (University of Minnesota) Technician – Islet Cell Isolation (King’s College Hospital NHS Foundation Trust) Postdoctoral Fellow – Pancreatic Development & Islet Biology (Vanderbilt University) Junior Scientists – Diabetes (Lund University) Postdoctoral Position – Pancreatic Tissue Engineering (King’s College London) Postdoctoral Research Assistant – Stem Cell and Cancer Research (University of Oxford) Professor – Diabetes (University of California, San Diego) Postdoctoral Fellowship – Pancreatic Cancer (Dartmouth College) Postdoctoral Fellow – Neuroscience and Diabetes (The Child Health Institute of New Jersey) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|